CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Rhea-AI Summary

Science 37 announced it has surpassed enrollment goals for a Phase 2 clinical trial of a small molecule therapeutic for Cholestatic Pruritus, enrolling 21% of study participants using its Metasite™ and Patient Recruitment solutions.

Over a 20-month period from September 2022 to April 2024, Science 37 achieved 11 times the average enrollment speed of traditional research sites, enrolling an average of 1 patient per month.

This success highlights Science 37's ability to recruit patients from broader geographical areas, enhancing the efficiency of rare disease research.

These services are available to clinical research sponsors and CROs either as standalone offerings or integrated with their Virtual Site solutions.

Positive

• Science 37 surpassed its enrollment goals for a Phase 2 trial.
• Achieved 21% of study participants using Metasite™ and Patient Recruitment solutions.
• Enrollment rate was 11 times faster than traditional sites.
• Enrolled 1 patient per month compared to 0.1 patients per month at traditional sites.
• Recruitment solutions can access patients from broader geographical areas.
• Patient Recruitment services are available as standalone or integrated solutions.

Negative

• None identified in the press release.

Science 37 Enrolls 21% of Study Participants at 11x the Speed of Traditional Research Sites Through its Virtual Site and Patient Recruitment Solutions

RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Science 37, Inc., please note that the first sentence of the second paragraph has been revised. The corrected release follows:

Science 37 Holdings, Inc., a leader in enhancing patient access to clinical trials, announced the final enrollment figures from its 20-month engagement with a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders.

Science 37 augmented the recruitment and enrollment activities taking place at study sites nationwide for an ongoing Phase 2 trial in patients with Cholestatic Pruritus. The study protocol mandated a highly specific patient population, requiring participants to undergo evaluation against rigorous inclusion and exclusion criteria.

Leveraging its proprietary Metasite™ and Patient Recruitment solutions, Science 37 contributed 21% of all randomized study participants between September 2022 and April 2024. Science 37 surpassed its contracted enrollment goal, achieving an average enrollment rate of 1 patient per month, compared to the 0.1 patients per month rate at each of the 51 participating traditional brick-and-mortar sites.

“Traditional recruitment methods are geographically limited, whereas Science 37 can recruit and enroll patients located anywhere, not just within a certain travel radius of a trial site. This significantly broadens the pool of qualified participants, which is vital for rare disease research,” explained Erica Prowisor, SVP of Patient and Provider Networks at Science 37.

Science 37’s Patient Recruitment is available on a standalone basis to clinical research sponsors and CROs looking to enhance their patient enrollment efforts, or in combination with Science 37’s industry-leading flagship Virtual Site, the Metasite™, as part of an accelerated research offering. For more information, please visit www.science37.com.

About Science 37

Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration. To learn more, visit www.science37.com, or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.

Media Inquiries

Science 37
PR@science37.com

FAQ

What enrollment goals did Science 37 surpass in the Phase 2 clinical trial for Cholestatic Pruritus?

Science 37 surpassed its enrollment goals by enrolling 21% of study participants and achieving 11 times the average enrollment speed of traditional sites.

What is the average enrollment rate achieved by Science 37 in the Phase 2 trial for SNCE?

Science 37 achieved an average enrollment rate of 1 patient per month, compared to 0.1 patients per month at traditional research sites.

How did Science 37 enhance patient recruitment for the Phase 2 trial of Cholestatic Pruritus?

Science 37 used its proprietary Metasite™ and Patient Recruitment solutions to enhance patient recruitment, enabling access to a broader geographical pool of participants.

What time period does the Science 37 enrollment achievement cover for the Phase 2 trial of SNCE?

The enrollment achievement covers a 20-month period from September 2022 to April 2024.

Can Science 37's Patient Recruitment services be used independently?

Yes, Science 37's Patient Recruitment services are available as standalone offerings or can be integrated with their Virtual Site solutions.